ADC Therapeutics Net Worth
ADC Therapeutics Net Worth Breakdown | ADCT |
ADC Therapeutics Net Worth Analysis
ADC Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ADC Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ADC Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ADC Therapeutics' net worth analysis. One common approach is to calculate ADC Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ADC Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ADC Therapeutics' net worth. This approach calculates the present value of ADC Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ADC Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ADC Therapeutics' net worth. This involves comparing ADC Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ADC Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if ADC Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ADC Therapeutics' net worth research are outlined below:
| ADC Therapeutics is way too risky over 90 days horizon | |
| ADC Therapeutics appears to be risky and price may revert if volatility continues | |
| ADC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 69.28 M. Net Loss for the year was (157.85 M) with loss before overhead, payroll, taxes, and interest of (39.32 M). | |
| ADC Therapeutics SA currently holds about 376.78 M in cash with (123.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 67.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: What drives ADC Therapeutics SA stock price - Breakout stock performance - jammulinksnews.com |
ADC Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ADC Therapeutics SA. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ADC Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know ADC Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ADC Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ADC Therapeutics SA backward and forwards among themselves. ADC Therapeutics' institutional investor refers to the entity that pools money to purchase ADC Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2025-03-31 | 815.5 K | Ubs Group Ag | 2025-03-31 | 767.1 K | Blue Owl Capital Holdings Lp | 2025-03-31 | 733.6 K | Bnp Paribas Arbitrage, Sa | 2025-03-31 | 692.1 K | Vanguard Group Inc | 2025-03-31 | 652 K | Northern Trust Corp | 2025-03-31 | 496.1 K | Dafna Capital Management Llc | 2025-03-31 | 224.1 K | Aqr Capital Management Llc | 2025-03-31 | 201.2 K | Charles Schwab Investment Management Inc | 2025-03-31 | 194.3 K | Redmile Group, Llc | 2025-03-31 | 15.7 M | Prosight Management, Lp | 2025-03-31 | 9.5 M |
Follow ADC Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 359.24 M.Market Cap |
|
Project ADC Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.54) | (0.57) | |
| Return On Assets | (0.49) | (0.51) | |
| Return On Equity | 0.78 | 0.82 |
When accessing ADC Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ADC Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ADC Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in ADC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ADC Therapeutics SA. Check ADC Therapeutics' Beneish M Score to see the likelihood of ADC Therapeutics' management manipulating its earnings.
Evaluate ADC Therapeutics' management efficiency
ADC Therapeutics has return on total asset (ROA) of (0.2703) % which means that it has lost $0.2703 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0553) %, meaning that it created substantial loss on money invested by shareholders. ADC Therapeutics' management efficiency ratios could be used to measure how well ADC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.82 in 2025, whereas Return On Tangible Assets are likely to drop (0.51) in 2025. At this time, ADC Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 466.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 51 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.09) | (1.98) | |
| Tangible Book Value Per Share | (2.09) | (1.98) | |
| Enterprise Value Over EBITDA | (0.63) | (0.66) | |
| Price Book Value Ratio | (0.95) | (0.91) | |
| Enterprise Value Multiple | (0.63) | (0.66) | |
| Price Fair Value | (0.95) | (0.91) | |
| Enterprise Value | 65.5 M | 62.2 M |
ADC Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 3.7938 | Revenue | Quarterly Revenue Growth 0.276 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADC Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADC Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ADC Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ADC Therapeutics time-series forecasting models is one of many ADC Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ADC Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ADC Therapeutics Earnings per Share Projection vs Actual
ADC Therapeutics Corporate Directors
| Viviane Monges | Non-Executive Independent Director | Profile | |
| Thomas Pfisterer | Non-Executive Independent Director | Profile | |
| Tyrell Rivers | Non-Executive Independent Director | Profile | |
| Peter Hug | Non-Executive Independent Director | Profile |
Already Invested in ADC Therapeutics SA?
The danger of trading ADC Therapeutics SA is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADC Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADC Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADC Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.